Ningbo MedicalSystem Biotechnology Co Ltd Market Cap ($556.19 Million)
Market Cap & Net Worth: Ningbo MedicalSystem Biotechnology Co Ltd (300439)
Ningbo MedicalSystem Biotechnology Co Ltd market cap. Ningbo MedicalSystem Biotechnology Co Ltd (SHE:300439) has a market capitalization of $556.19 Million (CN¥3.80 Billion) as of November 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #11325 globally and #3109 in its home market, demonstrating a 4.88% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ningbo MedicalSystem Biotechnology Co Ltd's stock price CN¥9.89 by its total outstanding shares 384318815 (384.32 Million). Also see Ningbo MedicalSystem Biotechnology Co Lt cash flow conversion for how efficiently the company converts equity into cash flow.
Ningbo MedicalSystem Biotechnology Co Ltd Market Cap History (2015–2026)
Ningbo MedicalSystem Biotechnology Co Ltd market cap history from 2015 to 2026. Data shows change from $2.12 Billion to $556.19 Million (-10.27% CAGR). Check latest Ningbo MedicalSystem Biotechnology Co Lt stock price today for real-time trading data and today's change.
Ningbo MedicalSystem Biotechnology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ningbo MedicalSystem Biotechnology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Ningbo MedicalSystem Biotechnology Co Lt to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.34x
Ningbo MedicalSystem Biotechnology Co Ltd's market cap is 0.34 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.28x
Ningbo MedicalSystem Biotechnology Co Ltd's market cap is 2.28 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.12 Billion | $683.14 Million | $161.27 Million | 3.10x | 13.12x |
| 2016 | $1.60 Billion | $1.06 Billion | $174.49 Million | 1.51x | 9.17x |
| 2017 | $1.01 Billion | $2.58 Billion | $229.70 Million | 0.39x | 4.41x |
| 2018 | $714.78 Million | $3.14 Billion | $241.17 Million | 0.23x | 2.96x |
| 2019 | $734.33 Million | $3.13 Billion | -$576.63 Million | 0.23x | N/A |
| 2020 | $987.21 Million | $2.30 Billion | $299.48 Million | 0.43x | 3.30x |
| 2021 | $1.16 Billion | $2.25 Billion | $179.49 Million | 0.52x | 6.47x |
| 2022 | $642.19 Million | $2.49 Billion | $198.53 Million | 0.26x | 3.23x |
| 2023 | $643.17 Million | $1.89 Billion | $256.55 Million | 0.34x | 2.51x |
| 2024 | $587.69 Million | $1.74 Billion | $258.00 Million | 0.34x | 2.28x |
Competitor Companies of 300439 by Market Capitalization
Companies near Ningbo MedicalSystem Biotechnology Co Ltd in the global market cap rankings as of November 4, 2026. Also see how large is Ningbo MedicalSystem Biotechnology Co Lt's balance sheet for a full breakdown of the balance sheet.
Key companies related to Ningbo MedicalSystem Biotechnology Co Ltd by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #87 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #142 globally with a market cap of $162.54 Billion USD.
- Natera Inc (NASDAQ:NTRA): Ranked #479 globally with a market cap of $56.02 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #546 globally with a market cap of $48.96 Billion USD ( CN¥334.59 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #87 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $698.34 |
| #142 | Danaher Corporation | NYSE:DHR | $162.54 Billion | $230.11 |
| #479 | Natera Inc | NASDAQ:NTRA | $56.02 Billion | $388.63 |
| #546 | WuXi AppTec Co Ltd | SHG:603259 | $48.96 Billion | CN¥135.28 |
Market Capitalization of Ningbo MedicalSystem Biotechnology Co Ltd (2015–2026)
Market capitalization of Ningbo MedicalSystem Biotechnology Co Ltd from 2015 to today. Between 2015 and today, Ningbo MedicalSystem Biotechnology Co Ltd's market cap moved from $2.12 Billion to $ 556.19 Million, with a yearly change of -10.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥556.19 Million | +0.41% |
| 2025 | CN¥553.94 Million | -5.74% |
| 2024 | CN¥587.69 Million | -8.63% |
| 2023 | CN¥643.17 Million | +0.15% |
| 2022 | CN¥642.19 Million | -44.66% |
| 2021 | CN¥1.16 Billion | +17.55% |
| 2020 | CN¥987.21 Million | +34.44% |
| 2019 | CN¥734.33 Million | +2.74% |
| 2018 | CN¥714.78 Million | -29.51% |
| 2017 | CN¥1.01 Billion | -36.65% |
| 2016 | CN¥1.60 Billion | -24.32% |
| 2015 | CN¥2.12 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Ningbo MedicalSystem Biotechnology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $556.19 Million USD |
| MoneyControl | $556.19 Million USD |
| MarketWatch | $556.19 Million USD |
| marketcap.company | $556.19 Million USD |
| Reuters | $556.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ningbo MedicalSystem Biotechnology Co Ltd
Medicalsystem Biotechnology Co., Ltd. engages in the research, development, production, and sales of in vitro diagnostic products in China. It is also involved in the provision of Three-party medical diagnosis services. The company offers automated chemistry analyzers; and automated chemiluminescence immunoassay analyzer; hematology analyzers and reagents; total laboratory automation system; mass… Read more